Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease

Choi, Joo-Hyung; Jeong, Kwiwan; Kim, Su-Mi; Ko, Mi-Kyeong; You, Su-Hwa; Lyoo, Young S.; Kim, Byounghan; Ku, Jin‐Mo

doi:10.4142/jvs.2018.19.6.788

Cited by 17 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to 5-FU, it is mutagenic for many RNA viruses [62,[70][71][72][73][74][75]. Ribavirin has been in clinics for many years to treat HCV (in combination with pegylated interferon) [76], FMDV [77] and poliovirus [78]. Additionally, ribavirin in combination with interferon-α2a or α2b has been shown to inhibit MERS-CoV infection [79][80][81].…”

Section: -Fluorouracil (5-fu)mentioning

confidence: 99%

Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs

Neogi

Hill

Ambikan

et al. 2020

Preprint

View full text Add to dashboard Cite

Coronaviruses (CoVs) are positive-stranded RNA viruses that infect humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKUI1 leads to the common cold, short lasting rhinitis, cough, sore throat and fever. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and the newest SARS-CoV-2 (the causative agent of COVID-19) lead to severe and deadly diseases with mortality rates ranging between ~1 to 35% depending on factors such as age and pre-existing conditions. Despite continuous global health threats to human, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors.

show abstract

Section: -Fluorouracil (5-fu)mentioning

confidence: 99%

Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs

Neogi

Hill

Ambikan

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…We think that a complementary approach using antiviral molecules would be ideal to complement vaccination, reduce viral spreading in equine structures and contain EAV outbreaks. This is supported by a recent study showing that a global strategy based on vaccination combined with drug therapies enhances protection against foot-and-mouth disease 10 . In our study, we have developed a high-throughput cell-viability assay based on infected equine dermal cells.…”

mentioning

confidence: 62%

Replication of Equine arteritis virus is efficiently suppressed by purine and pyrimidine biosynthesis inhibitors

Valle-Casuso

Gaudaire

Martin-Faivre

et al. 2020

Sci Rep

View full text Add to dashboard Cite

RNA viruses are responsible for a large variety of animal infections. Equine Arteritis Virus (EAV) is a positive single-stranded RNA virus member of the family Arteriviridae from the order Nidovirales like the Coronaviridae. EAV causes respiratory and reproductive diseases in equids. Although two vaccines are available, the vaccination coverage of the equine population is largely insufficient to prevent new EAV outbreaks around the world. In this study, we present a high-throughput in vitro assay suitable for testing candidate antiviral molecules on equine dermal cells infected by EAV. Using this assay, we identified three molecules that impair EAV infection in equine cells: the broad-spectrum antiviral and nucleoside analog ribavirin, and two compounds previously described as inhibitors of dihydroorotate dehydrogenase (DHODH), the fourth enzyme of the pyrimidine biosynthesis pathway. These molecules effectively suppressed cytopathic effects associated to EAV infection, and strongly inhibited viral replication and production of infectious particles. Since ribavirin is already approved in human and small animal, and that several DHODH inhibitors are in advanced clinical trials, our results open new perspectives for the management of EAV outbreaks. Viruses with a RNA genome infect both animals and plants, and dominate the eukaryotic virome by their diversity and deleterious effects 1. Indeed, RNA viral infections are a substantial public health burden affecting humans and domestic animals 2. The pandemic of SARS-CoV-2 coronavirus is the latest and most striking example with thousands of deaths reported so far in different countries in the world. Horses are not an exception, and five of seven equine viruses listed by the World Organization for Animal Health are RNA viruses (OIE). Unfortunately, the veterinary therapeutic arsenal to fight against equine viral diseases is limited, or even not-existent as no antiviral molecule is listed today. During the last years, several studies have used high-throughput screening (HTS) techniques to scan small compound libraries that could impair the replication of equine viruses. These studies were mostly focused on zoonotic viruses like West-Nile virus 3,4. Non-zoonotic equine RNA viruses, such as equine arteritis virus (EAV), were not included in those screenings. Equine arteritis virus (EAV) is a positive-sense single-stranded RNA virus, member of the subfamily Equarterivirinae, member of the family Arteriviridae, genus Alphaarterivirus from order Nidovirales like the Coronaviridae. Equine viral arteritis disease is a recurrent viral infection that causes important economic losses to the horse industry. In most of the cases, EAV infection is subclinical, but some viral strains are virulent and induce fever with body temperature going up to 41 °C, depression, anorexia, edema, nasal discharge, and conjunctivitis. EAV is a virus transmitted by respiratory or venereal routes.

show abstract

“…Ribavirin is a synthetic nucleoside analogue that structurally resembles guanosine [45], and can interfere with the synthesis of viral mRNA. It has been demonstrated that ribavirin is a common anti-picornavirus drug with low cytotoxicity [46][47][48][49][50]. Its antiviral effect was generally described in terms of the SI value.…”

Section: Discussionmentioning

confidence: 99%

Construction of eGFP-Tagged Senecavirus A for Facilitating Virus Neutralization Test and Antiviral Assay

Liu

Huang

Wang

et al. 2020

Viruses

View full text Add to dashboard Cite

Senecavirus A (SVA), also known as Seneca Valley virus, is an emerging virus that causes vesicular disease in pigs. This virus belongs to the genus Senecavirus in the family Picornaviridae. The SVA CH-LX-01-2016 was isolated from Guangdong Province of China in 2016. In this study, a recombinant SVA CH-LX-01-2016 was constructed using reverse genetics, and proven to be able to express efficiently an enhanced green fluorescent protein (eGFP) in vitro. This eGFP-tagged recombinant SVA (rSVA-eGFP) exhibited a high capacity for viral replication. Its fluorescence-tracked characteristics greatly facilitated both virus neutralization test (VNT) and antiviral assay. The rSVA-eGFP-based VNT was used to detect eight porcine serum samples, out of which four were determined to be neutralization titer-positive. Subsequently, two antiviral drugs, ribavirin and apigenin, were assayed for evaluating both effects against the rSVA-eGFP in vitro. The result showed that only the ribavirin exhibited an anti-SVA activity.

show abstract

Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease

Cited by 17 publications

References 33 publications

Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs

Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs

Replication of Equine arteritis virus is efficiently suppressed by purine and pyrimidine biosynthesis inhibitors

Construction of eGFP-Tagged Senecavirus A for Facilitating Virus Neutralization Test and Antiviral Assay

Contact Info

Product

Resources

About